Log in or Sign up for Free to view tailored content for your specialty!
Lupus News
Innovative clinical trial designs, therapies for refractory disease top unmet needs in rheumatology
New treatments and trial designs, particularly focused on patients with refractory disease, remain among the top unmet needs in rheumatology in 2019, according to expert opinions culled from the Advances in Target Therapies annual meeting and published in the Annals of the Rheumatic Diseases.
AURORA study: Voclosporin safe, effective for lupus nephritis
Phase 3 results from the AURORA study demonstrated combining voclosporin with mycophenolate and low-dose corticosteroids was superior to standard care for treating patients with lupus nephritis. The results were made available through a press release from Aurinia Pharmaceuticals.
Log in or Sign up for Free to view tailored content for your specialty!
Podcasts driving a revolution in rheumatology medical education
When journalist Ben Hammersley coined the word “podcast” in 2004, he was attempting to put a name to the phenomenon resulting from the timely convergence of widely available MP3 player technology, inexpensive audio software and weblog culture — a renaissance of radio programs that could be downloaded and played at the listener’s convenience, anytime or anywhere.
Risk for immune-mediated inflammatory diseases 5-times higher in psoriasis
Among a large cohort of patients with psoriasis, researchers found around 20% had an immune-mediated inflammatory disease develop before psoriasis onset and 14% had one develop after psoriasis onset, according to a study using data from the Danish National Patient Registry.
Hair loss in systemic lupus may indicate active disease
Hair loss in systemic lupus erythematosus can indicate active disease, and nonscarring alopecia shows changes unique to lupus on histology and direct immunofluorescence, according to researchers in Journal of the American Academy of Dermatology.
Scarcity of lupus assays in developing countries limit utility of international criteria, trials
ATLANTA — Limited access to supportive laboratory assays in developing countries significantly reduces the diagnostic utility of the ACR/EULAR criteria for systemic lupus erythematosus, which relies on an antinuclear antibody titer of 1:80 for its entry criterion, noted a presenter at the 2019 ACR/ARP Annual Meeting.
TULIP-1: Anifrolumab fails primary endpoint, confers clinical benefit in SLE
ATLANTA — Although a 300 mg dose of anifrolumab failed to meet the primary endpoint of systemic lupus erythematosus responder index, a post-hoc analysis showed possible clinical benefit of the drug, according to a speaker at ACR/ARP 2019.
Study finds pathway for UVB light exposure as trigger for flares in SLE
ATLANTA — Upregulation of the cGAS-STING pathway may be implicated in disease flares of systemic lupus erythematosus that are triggered by exposure to ultraviolet B light, according to a speaker at ACR/ARP 2019.
Lupus Foundation of America encourages patient self-management
ATLANTA — The Lupus Foundation of America conducted two studies that aimed to help patients feel empowered and motivated to self-manage their disease, according to findings presented at ACR/ARP 2019.
Experts create algorithm for management of cutaneous manifestations in lupus
Researchers compiled a treatment algorithm for cutaneous manifestations of lupus erythematosus based on data from 104 studies, according to a study presented at the American College of Rheumatology/Association of Rheumatology Professionals annual meeting.